Analysis
Eli Lilly and Company (Lilly) characterized the overall financial impact of the U.S. tariffs introduced in April 2025—frequently referred to as the "Liberation Day" or reciprocal tariffs—as modest. Management consistently maintained that these trade policy shifts did not materially alter the company's financial outlook for FY2025. This limited impact was attributed partly to the initial exemption of pharmaceuticals from the reciprocal tariffs, which carried significantly higher rates for certain trading partners like China and the European Union. Despite these exemptions, Lilly remained subject to the baseline 10% supplemental tariffs imposed on nearly all imports starting in April 2025.
To mitigate potential long-term risks from tariffs and trade protection measures, Lilly has aggressively accelerated its reshoring strategy. Since 2020, the company has committed over $55B to U.S. manufacturing investments, including a $27B commitment announced in early 2025 for four new production facilities. Management expects that once this current manufacturing build-out is complete, the company will be able to supply the U.S. market entirely from domestic facilities, effectively insulating its U.S. supply chain from future import duties. However, Lilly has noted that shifting manufacturing to the U.S. can create headwinds for gross margins by reducing operational efficiency compared to a single-source global model and decreasing overall tax efficiency due to transfer pricing adjustments.
Lilly continues to view the trade environment as dynamic and unpredictable. In its FY-2025 Annual Report (10-K), the company warned that current pharmaceutical exemptions could be terminated or may not apply to future industry-specific tariffs. CEO Dave Ricks has also emphasized that while the company supports domestic investment goals, it advocates for tax incentives over tariffs, which he suggested could lead to retaliatory trade barriers in other geographies. This risk remains a focal point as the company manages its global footprint, with approximately 33% of its FY2025 revenue generated outside the United States.
While the reciprocal tariffs were initially struck down by the U.S. Supreme Court in February 2026, the administration immediately sought to re-impose baseline duties of 10% to 15% under separate legislative authority. Lilly's FY2026 guidance, issued in February 2026, was based on the "existing tariff and trade environment" and does not reflect further policy shifts. The company noted that it might not be able to meaningfully share the burden of any increased costs from future tariffs with payers or patients due to the highly regulated nature of pharmaceutical pricing and commercialization.
Data
The company has not provided a specific dollar quantification of tariff impacts, characterizing them as "modest." To mitigate these impacts, Lilly has scaled its U.S. manufacturing investments as shown below:
| U.S. Manufacturing Investment Commitments | Total ($B) |
|---|---|
| Total Investment Committed Since 2020 | $55.0 |
| of which announced in early 2025 | 27.0 |
Source: FY-2025 Earnings Transcript, Marvin Labs
Sources
The expected 2025 impact of currently announced tariffs is modest and has been factored into Eli Lilly and Company's 2025 guidance range.
Upon completion of our manufacturing agenda, we will be able to supply medicines for the U.S. market entirely from US facilities, as well as increase the volume of medicines we export.
The announced tariffs currently in effect do not materially change Eli Lilly and Company's 2025 financial outlook. However, the expansion of tariffs in other geographies or increases in retaliatory tariffs would have a negative effect on Lilly and for our industry.